XOMA Royalty Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
Monitoring Framework
Key Performance Indicators
Total Royalty and Contract Revenues Quarterly12.3M
Diluted Earnings Per Share (EPS) Quarterly0.2
Total Cash, Cash Equivalents, and Restricted Cash Quarterly138.7M
Watch Items
- Shareholder and Regulatory Approvals for Ligand MergerTrigger: Majority vote of XOMA combined voting power and HSR clearanceAction: Monitor proxy filings, shareholder vote outcomes, and regulatory notifications leading up to the expected Q3 2026 close.
- Janssen Biotech (Johnson & Johnson) Tremfya Litigation ProgressTrigger: Court rulings or settlement announcementsAction: Track legal updates as 75% of net proceeds from this litigation are tied to the Contingent Value Rights (CVRs) distributed to XOMA stockholders.
- Redemption of Series A and Series B Perpetual Preferred StockTrigger: Redemption date execution prior to merger closeAction: Verify the complete payout of accrued and unpaid dividends and redemption of preferred shares as required by the merger agreement.
Research as of 20 Jun 2026